

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BRUEMMENDORF ET AL.

APPLICATION NO: 10/583,107

FILED: 17 JULY 2007

FOR: COMBINATION OF (A) N-{5-[4-(4-METHYL-IPERAZINO-METHYL)-
BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-
PYRIMIDINE-AMINE AND (B) AT LEAST ONE HYPUSINATION
INHIBITOR AND THE USE THEREOF

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed June 15, 2006. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis
Pharma Intellectual Property
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-7824

Date: 4/14/09